MENLO PARK, Calif., June 29, 2012 /PRNewswire/ -- 3-V Biosciences, Inc., announced today the appointment of Douglas Buckley, PhD, as Vice President of Biology. Dr. Buckley brings more than 25 years of experience in the biopharmaceutical industry, and his discoveries and research leadership have resulted in several marketed products and many more in clinical development.
"With our lead antiviral program entering the clinic in the next year, we are committed to building a strong pipeline. Doug's extensive experience in target identification and prosecution and his track record of successful early-stage drug development will be instrumental to our continued growth," said George Kemble, PhD, 3-V's Chief Scientific Officer.
"I look forward to building upon the early successes of 3-V and developing the next generation of antiviral compounds with this team," said Dr. Buckley. "3-V has taken a novel approach to antiviral therapies that are less likely to allow viral resistance to develop. In addition, this approach opens up the possibility of developing high-value therapeutics in other therapeutic areas, making 3-V a compelling story."
Dr. Buckley joins 3-V from Exelixis, Inc., where he served most recently as Vice President of Biochemistry. In that role, he led research and discovery teams responsible for delivering over thirty IND-ready compounds to Exelixis' internal pipeline and to external partnerships. Also during his tenure at Exelixis, Dr. Buckley contributed to the New Drug Application filing for cabozantinib (XL 184). Prior to Exelixis, Dr. Buckley was the Department Head of Protein Chemistry and Process Development at Scios, Inc., where he was responsible for process and assay development for two marketed biotherapeutic products (Fiblast® (trafermin) and NATRECOR® (nesiritide)). Doug received his AB in Chemistry and Economics from Bowdoin College, his PhD in Endoc
|SOURCE 3-V Biosciences, Inc.|
Copyright©2012 PR Newswire.
All rights reserved